evidence boundary
supportsobservational
An evidence atom is an inspectable support unit. It is not a finding by itself; it supports or challenges a finding through review.
frontiers / frontier
Evidence atom
back to sourcesevidence boundary
supportsAn evidence atom is an inspectable support unit. It is not a finding by itself; it supports or challenges a finding through review.
finding binding
boundAducanumab approval did not establish a stable clinical translation pathway for anti-amyloid therapy because the program was discontinued after contested evidence and restricted uptake.
inspect finding →
source binding
source-boundvs_18c998c2035325a6
inspect source →
review context
unverified3 reviewable changes and 0 evaluation records target this atom or its bound objects.
Evidence statement
Aducanumab approval did not establish a stable clinical translation pathway for anti-amyloid therapy because the program was discontinued after contested evidence and restricted uptake.
locator
source:FDA approval materials, CMS coverage decisions, and sponsor discontinuation notices|section:curator_source
extraction method
manual_curation
support relation
supports
condition refs
vcnd_8377b45829323351
Caveats
No evidence-specific caveats are recorded.
events
vev_44f1a5f04c58fcf8finding.notedRegulatory source reg-fda-aducanumab changed tracked source fields: source locator changed from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/aduhelm-aducanumab-avwa-information to https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/aducanumab-marketed-aduhelm-information. Review whether this affects the linked finding scope, trial table, or decision brief; source metadata alone does not change the claim.
reviewer:will-blair-bot · 2026-05-06
vev_93f4fe25cdc8802efinding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
vev_d3ad8fcddb85049efinding.reviewedRegulatory history is factual, but its implication for the anti-amyloid class remains contested.
reviewer:will-blair-bot · 2026-05-06
reviewable changes
vpr_1d0faeb172ca1b81finding.noteReview regulatory source record delta for reg-fda-aducanumab from run sir_4c5bbc2d54bb56be
applied · reviewer:will-blair-bot · 2026-05-06
vpr_3ac95fdf616023a7finding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
vpr_e242b8fa10d4df8cfinding.reviewRegulatory history is factual, but its implication for the anti-amyloid class remains contested.
applied · reviewer:will-blair-bot · 2026-05-06
evaluations
No evaluation rows are attached.